CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+49.77%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$664M
AUM Growth
+$664M
(+6.7%)
Cap. Flow
+$28.1M
Cap. Flow
% of AUM
4.24%
Top 10 Holdings %
Top 10 Hldgs %
60.97%
Holding
41
New
11
Increased
8
Reduced
7
Closed
6
Top Buys
| 1 |
Nuvalent
NUVL
|
$27.2M |
| 2 |
Immunovant
IMVT
|
$20.4M |
| 3 |
Arcellx
ACLX
|
$18.3M |
| 4 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$14M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$13.3M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$43.3M |
| 2 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$22.3M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$20.7M |
| 4 |
Viridian Therapeutics
VRDN
|
$19.8M |
| 5 |
Akero Therapeutics
AKRO
|
$11.3M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $65.4M | 9.86% | 1,659,111 +64,179 | +4% | +$2.53M |
|
|
2
Viridian Therapeutics
VRDN
$1.5B
| $59M | 8.89% | 2,020,166 -676,174 | -25% | -$19.8M |
|
3
Cogent Biosciences
COGT
$1.69B
| $49.9M | 7.53% | 4,319,940 | – | – |
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $43.6M | 6.57% | 5,303,557 +175,000 | +3% | +$1.44M |
|
5
Merus
MRUS
$4.98B
| $42.3M | 6.37% | 2,732,567 +116,805 | +4% | +$1.81M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $36M | 5.42% | 5,738,500 | – | – |
|
7
Aclaris Therapeutics
ACRS
$209M
| $29.6M | 4.46% | 1,880,286 -530,336 | -22% | -$8.35M |
|
|
8
Akero Therapeutics
AKRO
$3.74B
| $29.4M | 4.44% | 537,076 -206,396 | -28% | -$11.3M |
|
|
9
Nuvalent
NUVL
$5.52B
| $27.2M | 4.1% | +913,621 | New | +$27.2M |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $22.1M | 3.33% | 495,823 -42,989 | -8% | -$1.92M |
|
|
11
Immunovant
IMVT
$2.56B
| $20.4M | 3.08% | +1,150,505 | New | +$20.4M |
|
12
Arrowhead Research
ARWR
$3.05B
| $18.7M | 2.82% | 462,111 +58,033 | +14% | +$2.35M |
|
13
Celcuity
CELC
$2.17B
| $18.6M | 2.8% | 1,327,952 +407,488 | +44% | +$5.71M |
|
|
14
Arcellx
ACLX
$3.85B
| $18.3M | 2.76% | +591,437 | New | +$18.3M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $17.5M | 2.64% | 688,445 -49,665 | -7% | -$1.26M |
|
16
Day One Biopharmaceuticals
DAWN
$769M
| $15.9M | 2.4% | 739,661 | – | – |
|
|
RXDX
17
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $14M | 2.11% | +127,156 | New | +$14M |
|
|
ALLK
18
DELISTED
Allakos
ALLK
| $13.8M | 2.09% | 1,643,500 | – | – |
|
19
Kura Oncology
KURA
$686M
| $13.6M | 2.06% | 1,099,407 +200,000 | +22% | +$2.48M |
|
|
20
4D Molecular Therapeutics
FDMT
$288M
| $13.3M | 2% | +598,385 | New | +$13.3M |
|
21
Avidity Biosciences
RNA
$5.99B
| $13.1M | 1.98% | +590,705 | New | +$13.1M |
|
22
Enanta Pharmaceuticals
ENTA
$180M
| $10.4M | 1.57% | 223,494 +120,000 | +116% | +$5.58M |
|
23
Enliven Therapeutics
ELVN
$1.2B
| $10.2M | 1.54% | +2,494,794 | New | +$10.2M |
|
|
ALPN
24
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $9.74M | 1.47% | 1,325,000 | – | – |
|
25
89bio
ETNB
$1.34B
| $9.65M | 1.45% | +758,244 | New | +$9.65M |
|